Trial Profile
Phase 3 trial of Imeglimin patients with chronic kidney disease (CKD) stages 3b/4, an underserved patient population
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 18 Sep 2020
Price :
$35
*
At a glance
- Drugs Imeglimin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 15 Sep 2020 According to a Poxel media release, further FDA interactions are expected during the second half of 2020.
- 20 Apr 2020 According to a Poxel media release, the company is working with Metavant who is in discussions with the U.S. Food and Drug Administration for the Imeglimin Phase 3 program in type 2 diabetes patients with chronic kidney disease (CKD) stages 3b/4, an underserved patient population.
- 16 Feb 2018 New trial record